JP2013544235A - 肺機能を改善する治療法 - Google Patents

肺機能を改善する治療法 Download PDF

Info

Publication number
JP2013544235A
JP2013544235A JP2013533226A JP2013533226A JP2013544235A JP 2013544235 A JP2013544235 A JP 2013544235A JP 2013533226 A JP2013533226 A JP 2013533226A JP 2013533226 A JP2013533226 A JP 2013533226A JP 2013544235 A JP2013544235 A JP 2013544235A
Authority
JP
Japan
Prior art keywords
antagonist
seq
human
antibody
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013533226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544235A5 (enExample
Inventor
ラファエラ・ファッジョーニ
リチャード・メイ
クリス・ケル
ネスター・モルフィノ
ロリン・ロスコス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2013544235A publication Critical patent/JP2013544235A/ja
Publication of JP2013544235A5 publication Critical patent/JP2013544235A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/08—Measuring devices for evaluating the respiratory organs
    • A61B5/087—Measuring breath flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
JP2013533226A 2010-10-15 2011-10-14 肺機能を改善する治療法 Pending JP2013544235A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39367710P 2010-10-15 2010-10-15
US61/393,677 2010-10-15
US201161508723P 2011-07-18 2011-07-18
US61/508,723 2011-07-18
PCT/EP2011/067947 WO2012049278A1 (en) 2010-10-15 2011-10-14 Therapies for improving pulmonary function

Publications (2)

Publication Number Publication Date
JP2013544235A true JP2013544235A (ja) 2013-12-12
JP2013544235A5 JP2013544235A5 (enExample) 2014-11-20

Family

ID=44800047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013533226A Pending JP2013544235A (ja) 2010-10-15 2011-10-14 肺機能を改善する治療法

Country Status (15)

Country Link
US (1) US20130281876A1 (enExample)
EP (1) EP2627673B1 (enExample)
JP (1) JP2013544235A (enExample)
CN (1) CN103328506A (enExample)
AU (1) AU2011315499A1 (enExample)
BR (1) BR112013009055A2 (enExample)
CA (1) CA2814431A1 (enExample)
DK (1) DK2627673T3 (enExample)
ES (1) ES2645368T3 (enExample)
HU (1) HUE034005T2 (enExample)
MX (1) MX2013004212A (enExample)
NO (1) NO2627673T3 (enExample)
PL (1) PL2627673T3 (enExample)
RU (1) RU2013122123A (enExample)
WO (1) WO2012049278A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020509025A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ モノクローナル抗体製剤
JP2024160261A (ja) * 2020-07-31 2024-11-13 ジェネンテック， インコーポレイテッド 炎症性呼吸器疾患の増悪を治療するための方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
WO2015112970A1 (en) * 2014-01-27 2015-07-30 Medimmune, Llc Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EP3129497B1 (en) 2014-04-11 2021-09-08 Novartis AG Methods of selectively treating asthma using il-13 antagonists
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
AU2016205188A1 (en) 2015-01-09 2017-06-22 Medimmune, Llc Assay to detect human DPP-4
CN104605857A (zh) * 2015-02-12 2015-05-13 上海朔茂网络科技有限公司 一种肺功能测量方法
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
MA55204A (fr) 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
CN112341543B (zh) * 2021-01-11 2021-04-23 广东赛尔生物科技有限公司 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
JP2025501239A (ja) 2021-12-30 2025-01-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４／ｉｌ－１３アンタゴニストを投与することによってアトピーマーチを減弱する方法
WO2026151705A1 (en) * 2025-01-07 2026-07-16 Apogee Therapeutics, Inc. Dosage and administration of interleukin-13 antibody to treat asthma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537702A (ja) * 2003-07-15 2007-12-27 ケンブリッジ アンティボディー テクノロジー リミテッド Ｉｌ−１３に対するヒト抗体分子

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2140660A1 (en) * 1993-06-13 1994-12-22 Uwe R. Juergens Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
WO2006055638A2 (en) * 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537702A (ja) * 2003-07-15 2007-12-27 ケンブリッジ アンティボディー テクノロジー リミテッド Ｉｌ−１３に対するヒト抗体分子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5014000369; ＣＵＲＲＥＮＴ　ＯＰＩＮＩＯＮ　ＩＮ　ＩＮＶＥＳＴＩＧＡＴＩＯＮＡＬ　ＤＲＵＧＳ Ｖｏｌ．９，　Ｎｏ．１１, 20081101, ｐ．１１８０-１１８４ *
JPN6015034797; Ｂｒｉｔｉｓｈ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．６９，　Ｎｏ．６, 201006, ｐ．６４５-６５５ *
JPN6015034799; ＢＭＣ　ｐｕｌｍｏｎａｒｙ　ｍｅｄｉｃｉｎｅ Ｖｏｌ．１０, 201001, ｐ．３ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020509025A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ モノクローナル抗体製剤
JP2024160261A (ja) * 2020-07-31 2024-11-13 ジェネンテック， インコーポレイテッド 炎症性呼吸器疾患の増悪を治療するための方法

Also Published As

Publication number Publication date
HUE034005T2 (en) 2018-01-29
EP2627673A1 (en) 2013-08-21
BR112013009055A2 (pt) 2016-07-19
EP2627673B1 (en) 2017-07-26
DK2627673T3 (da) 2017-11-06
NO2627673T3 (enExample) 2017-12-23
US20130281876A1 (en) 2013-10-24
CN103328506A (zh) 2013-09-25
MX2013004212A (es) 2013-09-02
RU2013122123A (ru) 2014-11-20
PL2627673T3 (pl) 2018-01-31
WO2012049278A1 (en) 2012-04-19
ES2645368T3 (es) 2017-12-05
CA2814431A1 (en) 2012-04-19
AU2011315499A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
EP2627673B1 (en) Therapies for improving pulmonary function
JP2013544235A5 (enExample)
AU2018253118B2 (en) Treatment of asthma with anti-TSLP antibody
KR20170072197A (ko) 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
KR20240049348A (ko) 항-인터루킨-33 항체를 사용한 만성 폐쇄성 폐질환의 치료
JP2025527762A (ja) 抗インターロイキン－３３抗体を用いた喘息の治療
KR20230054444A (ko) 호흡기 질환 치료에 사용하기 위한 (1r,3s)-3-((5-시아노-4-페닐티아졸-2-일)카바모일)사이클로펜탄-1-카르복시산 및 이의 유도체
CN115867577A (zh) 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
EP4644416A2 (en) Interleukin 5 binding protein dosage regimen
TW201842933A (zh) 使用il-17拮抗劑選擇性治療氣喘的方法
US20250002598A1 (en) Methods of Treating Asthma with Anti-LIGHT Antibodies
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
HK1188603A (en) Therapies for improving pulmonary function
HK1188603B (en) Therapies for improving pulmonary function
HK40114122A (en) Methods of treating asthma with anti-light antibodies
CN118488968A (zh) 用抗light抗体治疗哮喘的方法
WO2025120567A1 (en) Method of treatment of asthma
WO2026041740A1 (en) Treatment of high-risk asthma by blocking il-13 and tslp
KR20260013478A (ko) 항-tslp 항체를 사용한 코르티코스테로이드 의존성 천식의 치료
HK40129804A (zh) 用抗白介素-33抗体治疗慢性阻塞性肺病
HK40130432A (en) Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160216